Carl L. Gordon Acquires 143,170 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon acquired 143,170 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $10.84 per share, with a total value of $1,551,962.80. Following the transaction, the director now directly owns 3,255,000 shares in the company, valued at approximately $35,284,200. This represents a 4.60 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MBX Biosciences Stock Up 5.4 %

MBX Biosciences stock opened at $11.83 on Friday. MBX Biosciences, Inc. has a 1-year low of $8.63 and a 1-year high of $27.50. The stock has a fifty day simple moving average of $14.05.

Hedge Funds Weigh In On MBX Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new position in MBX Biosciences in the 4th quarter worth $27,000. Virtus ETF Advisers LLC purchased a new position in MBX Biosciences in the 4th quarter worth $64,000. The Manufacturers Life Insurance Company raised its stake in MBX Biosciences by 7.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 49,675 shares of the company’s stock worth $916,000 after acquiring an additional 3,481 shares during the last quarter. Deutsche Bank AG purchased a new position in MBX Biosciences in the 4th quarter worth $80,000. Finally, Corebridge Financial Inc. purchased a new position in MBX Biosciences in the 4th quarter worth $103,000.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.